BioCentury
ARTICLE | Strategy

Takeda rides Denali’s ATV

Denali deal reflects Takeda’s growing commitment to biologics for CNS disorders

January 25, 2018 11:13 PM UTC

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with biologics. As the pharma continues to ramp up the therapeutic area, the Denali system could provide a gateway technology for other assets acquired or grown in house.

Since the arrival of CSO and CMO Andrew Plump in 2015, Takeda Pharmaceutical Co. Ltd. has been increasingly looking externally for modalities that can complement its expertise in small molecules...